MedWatch

Sanofi: Difficult to increase value through molecular route

According to the management of the French company’s diabetes division the coming decade will not necessarily be driven by molecular innovation. Find out more about where Sanofi sees innovation headed in the future.

Foto: Sanofi/PR

Berlin: The next ten years might not be driven by molecular innovation, instead we might see a paradigm shift in terms of how patients are handled, according to medical director of Sanofi’s diabetes division, Ricardo Perfetti.

“We are mostly focusing on additional examinations of the potential of GLP-1s. It’s not a done deal; it will be a fun ride for some time to come. And there might be greater advantages in terms of a better handling of existing drugs; a better administration of insulin through for example improved glucoses measuring equipment,” the executive tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Dansk Biotek skifter navn

Den danske brancheorganisation for biotekselskaber, Dansk Biotek, skifter navn til "Danish Bio - Dansk Biotek" for at imødekomme den stigende internationalisering af branchen, fortæller formand.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier